JNJ•benzinga•
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
Summary
LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 28, 2025 by benzinga